Tag: Lupin

The company has established a state-of- the-art 45,000 sq. ft National Reference Laboratory in Navi Mumbai

Innovation, R&D, partnership & policy support to be key growth drivers as echoed at Global Innovation Summit-2021 organized by Indian Pharmaceutical Alliance

As a part of the transaction, Generic Health will gain access to over 60 registered products having sales of over AUD 30 Mn (approximately USD 22 Mn)...................

The Biologics License Application (BLA) submission is supported by similarity data from analytical, pharmacokinetic, pharmacodynamic and immunogenicity studies........................

Lupin’s proprietary MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim’s KRAS inhibitor pipeline to address KRAS-driven cancer...........................

The investment has been made with a view to develop a world-class pharmaceutical supply chain & distribution IT ecosystem and support the government’s National Digital Health Mission.............................

Nepexto is Lupin’s biosimilar etanercept approved for all indications of the reference product Enbrel. It is available as an injectable in an easy-to-use pre-filled pen and a pre-filled syringe...................

Lupin Limited has announced the launch of its Favipiravir in India under the brand name Covihalt® for the treatment of mild to moderate COVID-19...................

The alliance aims to support the whole journey and experience of a respiratory patient right from diagnosis to treatment................

ADHERO device is India’s first connected device for metered-dose inhalers (MDI).................